A retrospective study including 6 cases of breast cancer patients with dose reductions and treatment delays due to thrombocytopenia secondary to T-DM1 or T-DXd therapy was reported to show efficacy in the treatment of immune thrombocytopenia after the use of thrombopoietin receptor agonists (TPO-RA) such as eltrombopag, romiplostim, and avatrombopag (Rainone et al., 2023a). Here, MPL is linked to breast carcinoma.